IL-17 Blockade to Decrease irAEs (REPLAY) - Clinical Trial
What is the Purpose of this Study?
If you decide to join the study, you will first have a check-up to make sure you can take part. If you are able to join, you will get a medicine called Secukinumab a few days before starting your cancer treatment again. You will get this medicine once a week for 4 weeks, then once every 4 weeks while you keep getting cancer treatment. After you stop both treatments, doctors will check on you for up to 3 years. During the study, you will have check-ups, blood tests, and small samples taken from your tumor.
This study is for people who have a kind of skin cancer called metastatic melanoma. It is for patients who have already tried a certain kind of cancer treatment called immune checkpoint inhibitors. These patients also had side effects like problems with their stomach, liver, skin, or joints.
Who Can Participate in the Study?
This study is for adults who have a serious kind of skin cancer called metastatic melanoma. It is for people who are planning to get certain cancer treatments, like PD-1 therapy or a mix of PD-1 with other medicines. It is also for people who had this kind of treatment before but had to stop because of bad side effects.
What is Involved?
The purpose of this study is to see if it is safe and possible to give a medicine called Secukinumab to people in this group. This medicine blocks a protein called IL-17A, which causes swelling and inflammation in the body. Doctors hope that by giving this medicine along with cancer treatment, they can stop bad side effects from coming back and help patients stay on their cancer treatment longer.
Study Details
